Comparable endemic coronavirus nucleoprotein-specific antibodies in mild and severe Covid-19 patients
Artikel i vetenskaplig tidskrift, 2021

The severity of disease of Covid-19 is highly variable, ranging from asymptomatic to critical respiratory disease and death. Potential cross-reactive immune responses between SARS-CoV-2 and endemic coronavirus (eCoV) may hypothetically contribute to this variability. We herein studied if eCoV nucleoprotein (N)-specific antibodies in the sera of patients with mild or severe Covid-19 are associated with Covid-19 severity. There were comparable levels of eCoV N-specific antibodies early and during the first month of infection in Covid-19 patients with mild and severe symptoms, and healthy SARS-CoV-2-negative subjects. These results warrant further studies to investigate the potential role of eCoV-specific antibodies in immunity to SARS-CoV-2 infection.

COVID‐19

disease severity

endemic coronaviruses

nucleoprotein‐specific antibodies

Författare

Susannah Leach

Göteborgs universitet

Sahlgrenska universitetssjukhuset

Ali M. Harandi

University of British Columbia (UBC)

Göteborgs universitet

Tomas Bergstrom

Göteborgs universitet

Lars-Magnus Andersson

Göteborgs universitet

Sahlgrenska universitetssjukhuset

Staffan Nilsson

Chalmers, Matematiska vetenskaper, Tillämpad matematik och statistik

Göteborgs universitet

Lia van der Hoek

Universiteit Van Amsterdam

Magnus Gisslen

Sahlgrenska universitetssjukhuset

Göteborgs universitet

Journal of Medical Virology

0146-6615 (ISSN) 1096-9071 (eISSN)

Vol. In Press

Ämneskategorier

Infektionsmedicin

Gastroenterologi

Reumatologi och inflammation

DOI

10.1002/jmv.27038

PubMed

33913546

Mer information

Senast uppdaterat

2021-05-20